Imfinzi vs. Tecentriq

Imfinzi (durvalumab) and Tecentriq (atezolizumab) Injection for intravenous infusion are monoclonal antibodies used to treat patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Side effects of Imfinzi and Tecentriq that are similar include fatigue, constipation, decreased appetite, nausea, swelling of extremities, urinary tract infection (UTI), abdominal pain, diarrhea/colitis, fever, shortness of breath, cough, and rash.

Side effects of Imfinzi that are different from Tecentriq include musculoskeletal pain.

Side effects of Tecentriq that are different from Imfinzi include vomiting, back or neck pain, joint pain, anemia, dehydration, itching, intestinal obstruction, urinary obstruction, blood in the urine (hematuria), acute kidney injury, venous thromboembolism, severe infection (sepsis), and pneumonia.

Both Imfinzi and Tecentriq may interact with other drugs.

Common side effects of Imfinzi include:

• fatigue,
• musculoskeletal pain,
• constipation,
• decreased appetite,
• nausea,
• swelling of extremities,
• urinary tract infection,
• abdominal pain,
• diarrhea/colitis,
• fever,
• shortness of breath,
• cough, and
• rash.

Common side effects of Tecentriq include:

• fatigue
• decreased appetite
• nausea
• vomiting
• constipation
• diarrhea
• abdominal pain
• urinary tract infection
• fever
• swelling of the extremities
• back or neck pain
• joint pain
• anemia
• dehydration
• itching
• rash
• intestinal obstruction
• urinary obstruction
• blood in the urine (hematuria)
• shortness of breath
• cough
• acute kidney injury
• venous thromboembolism
• severe infection (sepsis)
• pneumonia

Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Tecentriq (atezolizumab) Injection for intravenous infusion is a monoclonal antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (cancer) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Imfinzi may interact with other drugs. Tell your doctor all medications and supplements you use.

Tecentriq may interact with other drugs. Tell your doctor all medications and supplements you use.

Administer Imfinzi in a dose of 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

The recommended dose of Tecentriq is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.